Polymer lung surfactants
AssigneePurdue Research Foundation
InventorsYou-Yeon Won, Hyun Chang Kim
Life of this patent
Estimating the term…
Abstract
Disclosed herein are fully synthetic polymer-based lung surfactant materials, for the first time, as next generation SRT. In vitro studies on these polymer lung surfactants show that the candidate materials effectively mimic the surface tension controlling properties of currently marketed natural lung surfactants. Further, the polymer lung surfactants have strong protein resistance, which makes this class of materials promising also for potential use in Acute Respiratory Distress Syndrome (ARDS) treatment.
Claims21
A method of treating a pulmonary disorder of a mammal caused by deficiency and/or deactivation of functional lung surfactant in said mammal, the method comprising:
- administering to said mammal a therapeutically effective amount of a polymer lung surfactant composition, wherein the polymer lung surfactant composition comprises a synthetic biocompatible amphiphilic block copolymer, wherein the hydrophilic (water soluble) block comprises a monomer selected from the group consisting of ethylene glycol (EG), ethylene oxide (EO), vinyl alcohol (VA), and oxazoline (OZ), wherein the hydrophobic (water-insoluble) block copolymer comprises a monomer selected from the group consisting of lactic acid or lactide (LA), glycolic acid or glycolide (GA), caprolactone (CL), methacrylate (MA), acrylate (Ac), butadiene (BD), and isoprene (IP), and wherein said polymer lung surfactant composition forms stable micelles in aqueous solution, wherein the micelles are used in uncomplexed form not loaded with any other therapeutic agents.
A therapeutic lung surfactant formulation comprising a synthetic biocompatible or biodegradable amphiphilic block copolymer, wherein the hydrophilic (water-soluble) block comprises a monomer selected from the group consisting of ethylene glycol (EG), ethylene oxide (EO), vinyl alcohol (VA), and oxazoline (OZ), wherein the hydrophobic (water-insoluble) block comprises a monomer selected from the group consisting of styrene (PS), lactic acid or lactide (LA), glycolic acid or glycolide (GA), caprolactone (CL), methacrylate (MA), acrylate (Ac), butadiene (BD), and isoprene (IP), and wherein said polymer lung surfactant composition forms stable micelles in aqueous solution, wherein the micelles are in uncomplexed form not loaded with any other therapeutic agents.
A bulk or aerosolized liquid composition used as a lung surfactant comprising about 0.02-40 wt. % of amphiphilic block copolymers dispersed in micelle form in an aqueous or aqueous saline solution at the time of administration to a patient, wherein the micelle is used in uncomplexed form not loaded with any other therapeutic agents.
A bulk or aerosolized liquid composition used as a polymer lung surfactant comprising, at the time of administration to a patient, about 0.02-40 wt. % amphiphilic block copolymers dispersed in micelle form in aqueous or aqueous saline solution, wherein the amphiphilic block copolymer compound comprises a hydrophilic block (e.g., PEG) having an average molecular weight in the range between about 50 Da and about 1000 kDa and a hydrophobic block (e.g., PS) having an average molecular weight in the range between about 50 Da and about 1000 kDa, wherein the micelle is used in uncomplexed form not loaded with any other therapeutic agents.
Dependencies are inferred from the claim text.